Abediterol (INN) is an experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease. It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. It acts as a β2-adrenergic agonist.
|This pharmacology-related article is a stub. You can help WikiMD by expanding it.|